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Decreased endothelial nitric oxide (NO) bioavailability as 
it relates to endothelial dysfunction plays an important 
role in various cardiovascular disorders, including 
atherosclerosis. Recent research has provided evidence 
that endothelial dysfunction in atherosclerosis are not 
primarily caused by decreased endothelial NO synthase 
(eNOS) gene expression, but rather deregulation of 
eNOS enzymatic activity, which contributes to the 
increased oxidative stress in atherosclerosis. Among other 
mechanisms, the substrate L-arginine is an important 
limiting factor for NO production. Emerging evidence 
demonstrates that L-arginine is not only converted to NO 
via eNOS, but also metabolized to urea and L-ornithine via 
arginase in endothelial cells. Hence, arginase competes 
with eNOS for the substrate L-arginine, resulting in 
deceased NO production. There are an increasing number 
of studies showing that enhanced arginase gene 
expression and/or activity contribute to endothelial 
dysfunction in various cardiovascular disorders, including 
atherosclerosis. Thus, endothelial arginase may represent 
a new therapeutic target in atherosclerosis. 
Introduction 
Atherosclerotic coronary artery disease remains the leading 
cause of death in industrialized countries, despite the 
remarkable progress being made toward understanding the 
mechanisms and therapeutic modalities in recent decades [1]. 
Pathogenesis of atherosclerosis is a complex process involving 
vasoconstriction, intimal thickening, and thrombus formation 
[1]. Dysfunctions of numerous cell types in the vascular wall 
(ie, endothelial and smooth muscle cells) and circulating blood 
(ie, platelets and white blood cells) all contribute to the disease 
process [1]. Research in recent decades provides substantial 
evidence that endothelial dysfunction as it relates to decreased 
bioavailability of endothelial nitric oxide (NO) plays an 
important role in atherogenesis [2,3].  
Endothelium-derived NO is produced from the substrate 
L-arginine via endothelial NO synthase (eNOS), promotes 
vasodilation, and inhibits inflammation, platelet aggregation, 
and vascular smooth muscle cell (SMC) proliferation [4]. It is, 
therefore, not surprising that loss of endothelial NO function 
initiates and accelerates atherogenesis, as demonstrated by 
various experiments with animal models [5,6]. Although our 
understanding of biochemical regulation of endothelial NO 
bioactivity has remarkably advanced on various levels of eNOS 
gene expression—eNOS enzymatic activity to degradation of 
NO [7]—no single mechanism can fully explain endothelial 
dysfunction in atherosclerosis. Initial studies suggest that 
endothelial dysfunction in atherosclerosis is due to a decrease in 
eNOS gene expression [8]. Research in more recent years, 
however, provides evidence suggesting that reduced NO 
bioavailability, mainly due to a decrease in eNOS enzymatic 
activity rather than eNOS gene expression and accelerated 
inactivation of NO by oxidative stress, is the central mechanism 
of endothelial dysfunction in atherosclerosis [9]. This 
conclusion is supported by most studies of atherosclerotic 
animal models, showing an unchanged or even augmented 
protein level of eNOS in atherosclerotic arteries, despite the 
presence of endothelial dysfunction [10–12,13••]. Moreover, 
studies with human aortic and coronary arterial tissues obtained 
from autopsy or from transplant donors found only a 
significantly deceased eNOS gene expression in endothelial 
cells in advanced but not early atherosclerotic lesions [14,15]. 
Most recently, a study with human coronary atherectomy 
specimens showed a higher eNOS gene expression in patients 
with acute coronary syndromes than those with stable angina 
[16]. It is of particular importance to note that Ozaki et al. [17] 
recently showed acceleration of atherosclerotic lesion formation 
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in ApoE-/- mice overexpressing bovine eNOS transgene. 
Controversial results were, however, reported by van Haperen 
et al. [18] with the same experimental approach. The 
discrepancies in the results of the two studies are not clear. It 
has been speculated that the difference in severity of 
hypercholesterolemia and/or changes in blood pressure in 
animals between the two studies may explain the controversial 
results. Based on the outcomes of these, it can be asserted that 
endothelial dysfunction in atherosclerosis is not primarily 
caused by decreased eNOS gene expression. The studies also 
implicate that eNOS gene transfer into atherosclerotic arteries, 
which was initially proposed as a therapeutic approach to treat 
atherosclerosis, may not be generalized and should be carefully 
revisited. It is emerging that functional change in eNOS 
enzymatic activity rather than eNOS gene suppression plays an 
important role in endothelial dysfunction in atherosclerosis.  
Controversy of L-Arginine Supplemental 
Therapy in Atherosclerosis
The enzymatic activity of eNOS is affected by multiple factors, 
including post-translational modification associated with 
subcellular localization; the interacting proteins such as 
caveolin-1 and heat shock protein 90; and 
phosphorylation/dephosphorylation by protein kinases 
stimulated by hormonal agonists [7]. In addition, increase in 
endogenous eNOS inhibitor asymmetric dimethylarginine 
(ADMA), deficiency in co-factor tetrahydrobiopterin (BH4),
and deficiency in the substrate L-arginine have been proposed 
to cause so-called “uncoupling of eNOS” in atherosclerosis, a 
situation in which eNOS produces free radical superoxide anion 
instead of NO [17,19]. This mechanism may further contribute 
to inactivation of bioactive NO in atherosclerosis mediated by 
oxidative stress mediated by other enzymes such as NADPH-
oxidase [19].  
The bioavailability of L-arginine as a limiting factor for 
endothelial NO production was first recognized in the early 
1990s. Several groups demonstrated that acute and chronic 
supplementation of L-arginine improves endothelial vasodilator 
responses in cholesterol fed animals and in patients with 
hypercholesterolemia and atherosclerosis [20–23]. Following 
these early studies, numerous studies with supplemental L-
arginine therapy have been conducted in animal models and in 
humans; however, no consistent results can be achieved [24••]. 
In recent years, there has been an increasing number of studies 
showing either no effect or no sustained effects on endothelial 
function by L-arginine supplementation [6,25–30]. Harmful 
effects on atherosclerotic lesion formation in ApoE/iNOS 
double-knockout mice have been reported [31]. In this mouse 
model, the beneficial effect mediated by iNOS knockout on 
atherosclerotic lesion formation is eliminated with chronic L-
arginine supplementation [31]. In line with this report, an 
increase in superoxide anion production was also demonstrated 
in atherosclerotic rabbit aortas treated with L-arginine [32]. The 
reason for the inconsistent results with L-arginine
supplementation therapy is not clear. It might be due to the 
complex of the atherosclerotic disease process as well as the 
complex of biochemical metabolic pathways of the semi-amino 
acid L-arginine [33].  
Multiple Metabolic Pathways of L-Arginine
L-arginine, depending on cell types and tissues, undergoes 
multiple biochemical metabolisms and serves as precursor for a 
number of biologically active compounds involved in regulation 
of various cellular functions [33] (Fig. 1). As mentioned earlier, 
L-arginine is oxidized to NO and L-citrulline via eNOS in 
endothelial cells. Additionally, it is used for protein synthesis 
via arginyl t-RNA synthetase. L-arginine is also used for 
production of creatine via arginine:glycine amidinotransferase 
and guanidinoacetate N-methyltransferase, a pathway more 
restricted to the kidney and pancreas. Furthermore, L-arginine
can be converted to L-agmatine via arginine decarboxylase 
(ADC) and to L-ornithine and urea via arginase, which is part of 
the urea cycle. Urea is then excreted through the kidney (Fig. 
1). L-ornithine is further metabolized via ornithine 
decarboxylase (ODC) into polyamines that are important for 
cell proliferation [33]. L-ornithine can also be metabolized via 
ornithine aminotransferase (OAT) to L-proline, which is used 
for collagen production and deposition [33]. Hence, the 
production of polyamines and L-proline from L-arginine/L-
ornithine may play a role in negative vascular remodeling [34] 
(Fig. 1). Among the metabolisms, there is recently increasing 
evidence suggesting a potential role of arginase in regulation of 
endothelial NO production by competing with eNOS for the 
substrate L-arginine. Increase in arginase activity has recently 
been demonstrated to play an important role in endothelial 
dysfunction under several pathophysiologic conditions, 
including atherosclerosis (see later).   
Role of Arginase in Endothelial Dysfunction 
In mammals, there are two types of arginase, arginase I and II 
which are encoded by different genes [35]. Arginase I is a 
cytosolic enzyme, expressed most abundantly in the liver. The 
primary function of arginase I is ammonia detoxification. 
Arginase II is a mitochondrial enzyme, expressed primarily in 
the kidney or other extrahepatic tissues, including blood vessels 
[36]. The primary function of this type of enzyme is 
biosynthesis of polyamines and amino acids ornithine, proline, 
and glutamate [36]. Vascular endothelial and smooth muscle 
cells express both arginase I and II, but the relative level of the 
two types of enzyme seems different depending on species 
[13••,37–39]. In human endothelial cells, arginase II seems to 
be the predominant isoenzyme [13••,39]. The expression and 
activity of arginase II were found to be increased in human 
diabetic corpus cavernosum, and inhibition of the enzyme 
enhances NO-dependent relaxation of corpus cavernosum 
smooth muscle [40,41], suggesting a potential role for arginase 
II in negative regulation of NO production in diabetic erectile 
dysfunction. Similarly, arginase activity was also found to be 
higher in the aortas of type 1 and type 2 diabetic animal models 
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(Yang and Ming, Unpublished results). Our recent study 
demonstrates that in atherosclerotic aortas of ApoE-/- mice, 
arginase II was abundantly expressed, whereas arginase I was 
not detectable [13••]. Although the expression of arginase II 
was comparable between atherosclerotic and wild-type mice, 
the activity of the enzyme was increased in ApoE-/- animals, 
suggesting that increased enzymatic activity of arginase II plays 
a predominant role in atherosclerotic endothelial dysfunction.  
It is quite surprising that L-arginine causes 
vasoconstriction in isolated mouse aortas, which is in contrast 
to the observation in rats and humans in which L-arginine
evokes vascular relaxation by producing NO [13••]. Most 
interestingly, the contraction induced by L-arginine is much 
more pronounced in atherosclerotic ApoE-/- mice than in control 
animals. This contraction induced by L-arginine can be 
converted to a greater relaxation by the arginase inhibitor L-
norvaline in atherosclerotic ApoE-/- mice than that in wild-type 
animals [13••]. The results demonstrate a dominant role of 
increased arginase activity in atherosclerotic endothelial 
dysfunction. The results also imply that in mouse aortas, 
particularly in the atherosclerotic ApoE-/- aortas, and perhaps 
also in humans depending on the stage of atherosclerosis, L-
arginine can be metabolized by arginase to certain 
vasoconstrictive intermediate products. This hypothesis, if 
proven true, may explain the controversial results with L-
arginine supplementation therapy. In line with the greater 
vascular relaxation induced by L-arginine in the presence of the 
arginase inhibitor, eNOS protein levels are also higher in 
atherosclerotic ApoE-/- aortas than in the wild-type animals 
[13••]. The results further support the concept that endothelial 
dysfunction in atherosclerosis is mainly due to decreased NO 
bioavailability rather than gene expression. A simple 
administration of L-arginine alone as anti-atherosclerotic 
therapy should not be generalized. Future research designed to 
target arginase specifically in the vasculature may provide a 
novel therapeutic approach to treat atherosclerosis and perhaps 
also other cardiovascular disorders. 
Indeed, the role of arginase in endothelial dysfunction has 
been recently extended to other pathophysiologic conditions 
associated with vascular disorders in animal models such as 
aging [42,43], ischemia-reperfusion–induced endothelial 
dysfunction [44], and various types of hypertension 
[45,46,47••]. Most recently, the role of arginase in endothelial 
dysfunction has also been demonstrated in patients with 
primary pulmonary hypertension [48] and in patients with 
sickle cell disease [49••]. Importantly, arginase activity in blood 
plasma or red blood cells was found to be increased in patients 
with sickle cell disease, and is independently associated with 
pulmonary hypertension and mortality in these patients [49••].  
Regulation of Arginase Gene Expression and 
Activity in Endothelial Cells
Although there is evidence that arginase gene expression and/or 
activity is increased in various cardiovascular disorders, little 
information is available on the underlying regulatory 
mechanisms in the vasculature under the disease conditions, 
including atherosclerosis. Inflammatory cytokines have been 
shown to induce gene expression of arginase I and II in bovine 
endothelial cells, which is most likely mediated through 
transactivation of epidermal growth factor (EGF) receptors by 
the cytokines [50]. Our recent study provided the first evidence 
for the important role of RhoA/ROCK pathway in upregulation 
of arginase activity in human endothelial cells and in 
atherosclerotic blood vessels [13••]. We found that in human 
endothelial cells and atherosclerotic aortas of ApoE-/- mice, 
arginase I is not detectable by immunoblotting, whereas 
arginase II is abundantly expressed. Although the expression of 
arginase II is comparable in atherosclerotic and wild-type mice, 
the activity of the enzyme is significantly increased in ApoE-/-
animals, suggesting that increased enzymatic activity of 
arginase II plays a predominant role in atherosclerotic 
endothelial dysfunction. The higher arginase activity in the 
atherosclerotic aorta is associated with higher RhoA protein 
level, suggesting a role for RhoA in upregulation of arginase 
activity. Indeed, in cultured human endothelial cells, arginase II 
enzymatic activity, but not protein expression, is enhanced by 
thrombin, a potent activator of RhoA/ROCK in endothelial 
cells, after 18 to 24 hours of stimulation. The enhanced arginase 
activity can be prevented by inhibitors of the RhoA/ROCK 
pathway. In line with this observation, adenovirus-mediated 
ectopic expression of a constitutively active mutant of RhoA or 
ROCK significantly enhanced arginase activity but not the gene 
expression in the cells. The results suggest that the Rho/ROCK 
pathway stimulates arginase II via regulating the enzymatic 
activity rather than gene expression. This regulatory model of 
arginase II in human endothelial cells is further supported by a 
study by Bachetti et al. [39], who showed that arginase activity 
but not gene expression in the cells was increased after 24 hours 
of stimulation with inflammatory cytokine mixture. The exact 
regulatory mechanisms of arginase activity in the cells and in 
atherosclerotic blood vessels remain an interesting topic for 
future research.   
Conclusions
Endothelial dysfunction in atherosclerosis is primarily caused 
by functional changes in eNOS enzymatic activity. Among 
other mechanisms, vascular endothelial arginase is emerging to 
play a substantial role in endothelial dysfunction under various 
pathophysiologic conditions, including atherosclerosis. 
Enhanced endothelial arginase activity competes with eNOS for 
the substrate L-arginine, resulting in decreased NO production. 
Various studies showed that inhibition of vascular arginase 
activity improves endothelial dysfunction under various 
pathologic conditions. These results suggest that targeting 
endothelial arginase may represent a new therapeutic approach 
for treatment of atherosclerosis and other cardiovascular 
disorders.
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Figure 1. The multiple metabolic pathways of L-arginine. ADC—
arginine decarboxylase; eNOS—endothelial nitric oxide synthase; 
NO—nitric oxide; OAT— ornithine aminotransferase; ODC—ornithine 
decarboxylase; SMC—smooth muscle cell.   
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